Anteris Tech Global(AVR.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Anteris Tech Global
AVR.US
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp.
1.358 T
AVR.USMarket value -Rank by Market Cap -/-

Financial Score

23/01/2026 Update
E
Health Care EquipmentIndustry
Industry Ranking172/175
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-2462.72%E
    • Profit Margin-3941.94%E
    • Gross Margin71.33%A
  • Growth ScoreD
    • Revenue YoY-21.11%E
    • Net Profit YoY-18.59%D
    • Total Assets YoY-9.61%E
    • Net Assets YoY15.97%A
  • Cash ScoreD
    • Cash Flow Margin-2.54%D
    • OCF YoY-21.11%E
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreE
    • Gearing Ratio82.39%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Anteris Technologies Secures $320 Million for PARADIGM Trial

    Anteris Technologies Global Corp. has secured $320 million, including a $90 million strategic equity investment from Medtronic, to support its PARADIGM trial for the DurAVR® Transcatheter Heart Valve. The trial aims to compare DurAVR® with existing TAVR valves in a study of about 1,000 patients. Despite a Hold rating from analysts, the company is positioned to generate pivotal clinical evidence, although it faces challenges with declining revenue and large losses.

    Tip Ranks·
    US
    BBH
    -0.38%
    US
    AVR
    -1.37%
    US
    FBT
    -1.17%
    Tip Ranks·
    US
    BBH
    -0.38%
    US
    AVR
    -1.37%
    US
    FBT
    -1.17%

    Anteris Technologies Global Corp. Announces Closing Of $230 Million Public Offering Of Common Stock

    Anteris Technologies Global Corp :ANTERIS TECHNOLOGIES GLOBAL CORP. ANNOUNCES CLOSING OF $230 MILLION PUBLIC OFFERING OF COMMON STOCK

    Reuters·
    US
    AVR
    -1.37%
    Reuters·
    US
    AVR
    -1.37%

    Anteris Announces Strategic Investment From Medtronic To Continue Advancing Tavr In $320 Million Aggregate Capital Raises

    Anteris Technologies Global Corp :ANTERIS ANNOUNCES STRATEGIC INVESTMENT FROM MEDTRONIC TO CONTINUE ADVANCING TAVR IN $320 MILLION AGGREGATE CAPITAL RAISES

    Reuters·
    US
    AVR
    -1.37%
    US
    IHI
    -0.82%
    US
    MDT
    -0.45%
    Reuters·
    US
    AVR
    -1.37%
    US
    IHI
    -0.82%
    US
    MDT
    -0.45%

    Anteris Technologies Announces Major Equity Offering and Medtronic Deal

    Anteris Technologies Global Corp. announced a public offering of 34.8 million shares at $5.75 each, alongside a private placement with Medtronic's subsidiary for 15.7 million shares, totaling approximately $320 million. The funds will support the PARADIGM trial for its DurAVR heart valve and expand operations. The deal includes lock-up agreements and governance rights for Medtronic. Analysts rate AVR stock as a Hold with a $6.00 target, citing weak financial performance but positive technical indicators. Anteris focuses on transcatheter heart valve technologies.

    Tip Ranks·
    US
    IHI
    -0.82%
    US
    FBT
    -1.17%
    US
    BBH
    -0.38%
    Tip Ranks·
    US
    IHI
    -0.82%
    US
    FBT
    -1.17%
    US
    BBH
    -0.38%

    Anteris Technologies Announces $90 Million Private Placement to Medtronic Subsidiary

    Anteris Technologies Global Corp. has announced a $90 million private placement with Covidien Group, a subsidiary of Medtronic. The company will issue 15,652,173 shares at $5.75 each. The proceeds will support growth and clinical strategy. A registration rights agreement will be established for the investor to require registration and sale of the shares.

    Reuters·
    US
    IBB
    -1.30%
    US
    MDT
    -0.45%
    US
    AVR
    -1.37%
    Reuters·
    US
    IBB
    -1.30%
    US
    MDT
    -0.45%
    US
    AVR
    -1.37%
    © 2026 Longbridge｜Disclaimer